Tonghua Dongbao released its 2026 interim report. Operating revenue was 1.552 billion yuan, up 11.13% year on year. Net profit attributable to the parent was 296 million yuan, up 37.32% year on year. Net profit attributable to the parent after deducting non-recurring items was 296 million yuan, up 35.55% year on year. Net operating cash flow was 533 million yuan, up 62.42% year on year. Second-quarter operating revenue was 805 million yuan, up 11.5% year on year, and net profit attributable to the parent was 169 million yuan, up 55.5% year on year. The company said sales of insulin analogue products grew significantly, driving higher domestic sales revenue. Market access and sales volume for products such as insulin glargine and insulin aspart continued to increase. At the same time, through cooperation with Huisheng Biotech, it introduced insulin degludec and insulin aspart injection, and multiple products received overseas marketing approval.
Tonghua Dongbao Pharmaceutical Co LtdFirst-half net profit up 37.32% year on year, driven by strong sales of insulin analogues.
Cooperation with Tonghua Dongbao introduced insulin degludec and insulin aspart injection, expanding market access.
